Background Incidence, manifestations and case-fatality rate (CFR) of invasive
pneumococcal disease (IPD) vary with age and comorbidities. New vaccines, changing age …

Abstract Background Pneumococcal conjugate vaccines (PCVs) are highly effective in
preventing invasive pneumococcal disease (IPD), but deaths due to IPD still occur. We …

We studied the possible association between patient age and sex, clinical presentation,
Streptococcus pneumoniae serotype, antimicrobial resistance, and death in invasive …

With a retrospective study of invasive pneumococcal disease (IPD) surveillance data
representative for∼ 25% of the Dutch population (1275 hospitalized cases) over the period …

Within the European Union (EU), documenting the burden of invasive pneumococcal
disease (IPD) in infants and children is important for coordinating effective pneumococcal …

OBJECTIVES: Children with underlying conditions remain at increased risk for invasive
pneumococcal diseases (IPD). This study describes the epidemiology, serotype distribution …

To ascertain the factors linked to invasive pneumococcal disease (IPD) caused by the
different serotypes in the period 2007–2009, following the conjugate vaccine's inclusion in …

OBJECTIVE: To describe the epidemiology of invasive pneumococcal disease (IPD) in
England & Wales in the pre-conjugate vaccine era. METHODS: We analysed reports of …

The impact of the new pneumococcal conjugate vaccines on invasive disease burden in
Danish children was evaluated by analysing the results from the last 19 years of a …

Objective To identify a potential nadir of the impact of pneumococcal conjugate vaccination
(PCV) in infancy on invasive pneumococcal diseases (IPD) in children under 16 in Germany …